THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share.

加利福尼亚州千橡市，2026年8月6日（环球电讯社）——致力于开发创新型非阿片类镇痛药物的临床阶段生物制药公司Latigo Biotherapeutics, Inc.（“Latigo”）今日宣布，其扩大规模后的首次公开发行（IPO）已确定发行价格，将以每股18.00美元的价格向公众发行19,200,000股普通股。

All of the shares of common stock are being offered by Latigo. The gross proceeds to Latigo from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Latigo, are expected to be $345.6 million. In addition, the underwriters have a 30-day option to purchase up to an additional 2,880,000 shares of common stock at the public offering price, less underwriting discounts and commissions..

所有普通股股份均由Latigo公司发售。在扣除由Latigo支付的承销折扣、佣金及发行费用之前，本次发行预计将为Latigo带来3.456亿美元的毛收入。此外，承销商拥有30天的选择权，可按公开发行价格减去承销折扣和佣金后的净额，额外购买最多2,880,000股普通股。

The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol “LTGO.” The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.

预计该股票将于2026年8月7日在纳斯达克全球精选市场开始交易，股票代码为“LTGO”。在满足惯例交割条件的前提下，本次发行预计将于2026年8月10日完成交割。

Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering.

高盛集团与有限责任公司、杰富瑞、Leerink Partners 和古根海姆证券担任此次发行的联席账簿管理人。

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and has been declared effective by the SEC on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities.

与这些证券相关的注册声明已提交至美国证券交易委员会（SEC），并已于2026年8月6日获SEC宣布生效。注册声明的副本可通过SEC网站www.sec.gov获取。本次发行仅通过构成与这些证券相关的注册声明一部分的招股说明书进行。

When available, copies of the final prospectus relating to the initial public offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext.

如有提供，与首次公开发行相关的最终招股说明书副本可从以下机构获取：高盛集团有限责任公司（Goldman Sachs & Co. LLC），收件人：招股说明书部门，地址：纽约州纽约市西大街200号，邮编10282，电话：(866) 471-2526，电子邮件：prospectus-ny@ny.email.gs.com；杰富瑞有限责任公司（Jefferies LLC），收件人：股票承销招股说明书部门，地址：纽约州纽约市麦迪逊大道520号，邮编10022，电话：(877) 821-7388，电子邮件：Prospectus_Department@Jefferies.com；Leerink Partners LLC，收件人：承销部门，地址：马萨诸塞州波士顿市州街53号40层，邮编02109，电话：(800) 808-7525，分机

6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com..

6105，或通过电子邮件发送至 syndicate@leerink.com；或 Guggenheim Securities, LLC，收件人：股票承销部，地址：纽约州纽约市麦迪逊大道 330 号，邮编 10017，电话：(212) 518-9544，或通过电子邮件发送至 GSEquityProspectusDelivery@guggenheimpartners.com。

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，若根据该州或司法管辖区的证券法，在注册或资格认定之前进行此类要约、邀请或销售属违法行为，则不得在该州或司法管辖区销售这些证券。

Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended..

任何要约、招揽或购买要约，或任何证券销售，均将根据经修订的《1933年证券法》的注册要求进行。

About

关于

Latigo Biotherapeutics

拉蒂戈生物治疗公司

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo’s lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain..

Latigo Biotherapeutics 是一家临床阶段的生物制药公司，致力于开发创新的非阿片类镇痛药物，旨在阻断疼痛信号传递且无成瘾风险，从而提供有效、快速起效的疼痛缓解方案。Latigo 的核心候选产品 LTG-001 是一种口服 Nav1.8 抑制剂，旨在为急性疼痛治疗提供快速起效、减少阿片类药物使用的镇痛效果。

Forward-Looking Statements

前瞻性陈述

The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern our strategy, plans, projections or intentions.

本新闻稿中非历史事实的陈述均为前瞻性陈述。您可以通过其中包含的“相信”、“能够”、“估计”、“预期”、“打算”、“可能”、“计划”、“应当”、“寻求”或“将”等词语，或涉及我们的战略、计划、预测或意图的类似表述来识别前瞻性陈述。

These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to Latigo’s expected gross proceeds from the initial public offering, the expected date for Latigo common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering.

这些前瞻性陈述可能包含在本新闻稿的各个部分，包括但不限于有关Latigo首次公开发行预期募集资金总额、Latigo普通股在纳斯达克全球精选市场开始交易的预期日期以及首次公开发行预期完成的陈述。

By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Latigo’s expectations, beliefs and projections are expressed in good faith and Latigo believes there is a reasonable basis for them.

前瞻性陈述就其性质而言，并非对历史事实的陈述或对未来表现的保证，而是受到难以预测或量化的风险、不确定性、假设或情况变化的影响。Latigo 的预期、信念和预测均本着诚信原则作出，且 Latigo 认为其具有合理依据。

However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release.

然而，无法保证管理层的预期、信念和预测能够实现或达成，实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异。本新闻稿中的任何前瞻性陈述仅截至本新闻稿发布之日有效。

Latigo undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws..

Latigo 不承担公开更新或审查任何前瞻性陈述的义务，无论是否因新信息、未来发展或其他原因，除非适用的证券法律另有要求。

Company Contacts:

公司联系方式：

Investors:

投资者：

Neha Krishnamohan

尼哈·克里希纳莫汉

Latigo Biotherapeutics, Inc.

拉蒂戈生物治疗公司

ir@latigobio.com

ir@latigobio.com

Media

媒体

:

：

Kathy Vincent

凯西·文森特

Greig Communications, Inc.

格雷格通信公司

kathy@greigcommunications.com

kathy@greigcommunications.com